IDEAYA Biosciences, Inc. 8-K

What Happened
IDEAYA Biosciences (IDYA) announced on June 1, 2026 (via an 8‑K) that it and partner Servier presented complete primary‑analysis data from the registrational Phase 2/3 OptimUM‑02 trial at ASCO. The global trial enrolled 313 first‑line HLA*A2:01‑negative metastatic uveal melanoma patients randomized 2:1 to darovasertib plus crizotinib or investigator’s choice therapy (ICT). Data cutoff was January 23, 2026.

Key Details

• Trial primary (Phase 2) endpoint met: median progression‑free survival (PFS) by blinded independent central review (BICR) 6.9 months (darovasertib combo) vs. 3.1 months (ICT); HR 0.42; 95% CI 0.30–0.59; p < 0.0001.
• Investigator‑assessed median PFS: 6.7 months vs. 2.7 months (HR 0.36; 95% CI 0.26–0.50; p < 0.0001). Combo reduced progression risk by ~58% (BICR) and 64% (investigator).
• Response and disease control: ORR 37.1% (BICR) vs. 5.8% (ICT); DCR 73.3% vs. 31.1%. Median duration of response 6.8 months (median follow‑up 7.4 months).
• Safety and tolerability: Grade 3/4 treatment‑related AEs 40.6% (combo) vs. 37.0% (ICT); treatment‑related serious AEs 9.2% vs. 25.0%; low discontinuation for darovasertib (2.5%) and crizotinib (10.0%) vs. ICT (19.0%). Most common grade 3/4 TRAEs in combo: diarrhea (10.0%), syncope (7.1%), hypotension (3.8%).
• Regulatory status: FDA agreed to review the NDA under the Real‑Time Oncology Review (RTOR) program; IDEAYA completed the first pre‑submission in May and expects to complete the NDA filing in H2 2026. Overall survival (Phase 3 primary) data were immature at cutoff but showed an early trend favoring the combo; next OS update will be at the prespecified interim analysis.

Why It Matters
The OptimUM‑02 results show a statistically significant and clinically meaningful improvement in PFS and response rates for darovasertib plus crizotinib versus real‑world investigator choice in this metastatic uveal melanoma population—findings that support IDEAYA’s pursuit of accelerated approval (PFS is the primary endpoint used to seek accelerated approval). The ongoing FDA RTOR review and planned full NDA filing in H2 2026 could speed regulatory assessment; however, overall survival data (needed for full approval) remain immature and will be important for long‑term labeling and commercial prospects. Investors should note the safety profile and planned regulatory milestones reported in the filing.